CTLA4 and gastric cancer: The NEONIPIGA phase II trial was a French study designed for the MSI-H population in which locally advanced esophagogastric junction/gastric cancer patients (cT2-4,Nx) received six cycles of neoadjuvant nivolumab (anti-PDL1) every 2 weeks and also neoadjuvant ipilimumab (anti-CTLA4) for two cycles 6 weeks apart, followed by nine cycles of adjuvant nivolumab post-surgery.